{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:20:56Z","timestamp":1771269656850,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Therapeutic options in immune\u2010mediated thrombotic thrombocytopenic purpura (iTTP) during pregnancy are limited besides therapeutic plasma exchange (TPE) and corticosteroids. The report by Odetola et al. suggests that caplacizumab represents a reasonable option in iTTP during pregnancy, especially when the disease is not rapidly controlled with the standard TPE\u2013corticosteroid association.<\/jats:p><jats:p>Commentary on: Odetola et al. Safe and effective use of caplacizumab in pregnancy\u2010related acquired thrombotic thrombocytopenic purpura. Br J Haematol 2023;202:879\u2013882.<\/jats:p>","DOI":"10.1111\/bjh.18915","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:15:20Z","timestamp":1686287720000},"page":"725-727","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Caplacizumab: A game changer also in pregnancy\u2010associated immune\u2010mediated thrombotic thrombocytopenic purpura?"],"prefix":"10.1111","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-2095","authenticated-orcid":false,"given":"Paul","family":"Coppo","sequence":"first","affiliation":[{"name":"Service d'h\u00e9matologie AP\u2010HP. 6 and Sorbonne \u2013 Universit\u00e9  Paris France"},{"name":"Centre National de R\u00e9f\u00e9rence des Microangiopathies thrombotiques (CNR\u2010MAT) AP\u2010HP. 6 and Sorbonne \u2013 Universit\u00e9  Paris France"},{"name":"Centre de Recherche des Cordeliers INSERM UMRS1138  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9rang\u00e8re S.","family":"Joly","sequence":"additional","affiliation":[{"name":"Centre National de R\u00e9f\u00e9rence des Microangiopathies thrombotiques (CNR\u2010MAT) AP\u2010HP. 6 and Sorbonne \u2013 Universit\u00e9  Paris France"},{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Lariboisi\u00e8re, AP\u2010HP.Nord Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"EA3518, Institut de Recherche Saint\u2010Louis Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"French Reference Center for Thrombotic Microangiopathies (CNR\u2010MAT)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18888"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-553131"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15030"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000962"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.11.010"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17833"},{"key":"e_1_2_2_10_1","unstructured":"Takeda Newsroom [internet].Takeda announces favorable phase 3 safety and efficacy results of TAK\u2010755 as compared to standard of care in congenital thrombotic thrombocytopenic purpura (cTTP)[cited 2023 Jun 5]. Available from:https:\/\/www.takeda.com\/newsroom\/newsreleases\/2022\/takeda\u2010announces\u2010favorable\u2010phase\u20103\u2010safety\u2010and\u2010efficacy\u2010results\u2010of\u2010tak\u2010755\u2010as\u2010compared\u2010to\u2010standard\u2010of\u2010care\u2010in\u2010congenital\u2010thrombotic\u2010thrombocytopenic\u2010purpura\u2010cttp\/"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211113"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T02:35:09Z","timestamp":1725849309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/bjh.18915"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18915","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"2023-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}